Clinicians are increasingly being challenged by patients who are treated for chronic pain
with high-dose opioids that can cause medical, social, and societal harm. These patients …

Due to the prevalence of chronic pain and high-impact chronic pain in the US, a significant
percentage of the population is prescribed opioids for pain management. However, opioid …

With the ongoing public health crisis with prescription opioids, there is a need for safer
alternatives for medication management in chronic pain patients. Buprenorphine is a partial …

Objective An expert panel convened to reach a consensus on common misconceptions
surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for …

The federal Drug Abuse Treatment Act 2000 (DATA) opened a window of opportunity for
patients with the disease of addiction by providing increased access to options for treatment …

A growing number of patients are prescribed buprenorphine for opioid use disorder (OUD).
Consequently, clinicians are likely to encounter hospitalized patients with acute surgical or …

Background: Sublingual buprenorphine-naloxone (buprenorphine SL) is a preparation that
is used to treat opioid dependence. In addition, the Drug Enforcement Administration (DEA) …

Opioid dependence is epidemic in the United States, with increasing numbers addicted to
heroin and burgeoning abuse of prescription opioid analgesics. Buprenorphine, the most …

Reclassification of chronic pain as a disease may be helpful because patients with chronic
pain require significant treatment and rehabilitation with a clear diagnosis. This can help …

Objective To review the current evidence on buprenorphine-naloxone for the treatment of
opioid-related disorders, with a focus on primary care settings. Quality of evidence MEDLINE …